Total: $701.08M | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details (Date)@ |
| | ||||
Acusphere |
Sale of |
N/A |
$45 |
Acusphere sold 900,000 shares of 6.5% convertible exchangeable preferred stock at $50 per share; it is convertible into common stock at $6.86 per share; underwriters Piper Jaffray & Co. (lead), SG Cowen & Co. and C.E. Unterberg, Towbin have an overallotment option on another 100,000 shares (2/18) |
Alkermes |
Private placement of notes |
N/A |
$170 |
The 7% notes due 2018 will be paid solely from manufacturing and royalty revenues from sales of Risperdal Consta, a schizophrenia drug marketed by J& J unit Janssen-Cilag (2/3) |
BioBalance |
Private placement of stock and warrants |
7.9S and 3.9W |
$4.9 |
The shares were sold at $0.62 each; warrants are exercisable at $0.78 per share; investors included Mellon HBV Alternative Strategies and Little Gem Life Sciences Fund LLC; placement agent Sterling Financial Investment Group got warrants to purchase shares equal to 15% of the offering at $0.62 per share (2/24) |
BioCryst |
Private placement of stock |
4.35S |
$23.9 |
The shares were sold from a shelf registration at $5.50 each; Leerink Swann & Co. was placement agent (2/17) |
BioDelivery |
Convertible debt deal |
N/A |
$2.5 |
Laurus Master Fund Ltd. bought the three-year, prime-plus-2% note convertible into common stock at $3.10 per share; Laurus also got warrants to purchase up to 350,000 shares at $3.88 per share (2/23) |
Cytomedix |
Warrants and options exercise |
ND |
$1.4 |
Investors exercised about 1.1M warrants and options between Oct. 1, 2004, and Feb. 15, 2005 (2/15) |
Discovery |
Private placement of stock |
5.05S |
$29.1 |
Shares in the registered direct offering were sold at $5.76 each; SG Cowen & Co. LLC was placement agent (2/18) |
DOR |
Private placement of stock and warrants |
8.4S and 6.3W |
$3.77 |
Institutional investors purchased the stock and warrants; the five-year warrants are exercisable at 101% of the closing price the day of the deal, starting 180 days after the deal's close (2/3) |
Ecopia |
Bought-deal financing |
11U |
C$9.9 (US$8) |
Units, sold at C$0.90 each, consist of one share and one-third of a warrant; each two-year whole warrant allows for the purchase of one share at C$1.03; the underwriting syndicate was led by Desjardins Securities Inc. and included First Associates Investments Inc. and Orion Securities Inc.; the totals include their purchase of 1M units per their overallotment option (2/25) |
GeneMax Corp. |
Private placement of stock and warrants |
9.3S and 4.65W |
$1.4 |
The warrants are exercisable from $0.15 to $0.50 each, depending on the timing and other factors; finders' fees of 8% cash and 5% warrants were paid to certain brokers in the deal (2/15) |
GW |
Private placement of stock and warrants |
2.03S and 0.203W |
£2.5 (US$4.8) |
GW's U.S. founding investor increased its stake in the company with the purchase of shares at £1.235 per share; the five-year warrants are exercisable at £1.35 per share (2/28) |
MultiCell |
Private placement of stock and warrants |
26.67S and 26W |
$4 |
The shares were sold at $0.15 each; 18M of the three-year warrants are exercisable at $0.20 and 8M of them at $0.30; Mercator Group Advisors LLC and Marr Group were the lead investors (2/14) |
Neurologix |
Private placement of stock and warrants |
1.896S and 0.474W |
$2.46 |
The shares were sold at $1.30 each; the five-year warrants are exercisable at $1.625 per share; Merlin Biomed Group led the financing, which was done in two closings (2/11 and 2/25) |
Oncolytics |
Warrants exercise |
0.814S |
$3.25 |
Investors in a June 2003 financing exercised warrants for about 0.814M shares (2/22) |
Pharma- |
Private placement of convertible notes |
N/A |
$6.1 |
The $6.1M convertible notes will be automatically exchanged for stock if PharmaFrontiers raises $10M in a stock sale before the notes' maturity on Nov. 30, 2005 (2/14) |
Protein Design |
Private placement of convertible notes |
N/A |
$250 |
The 2% notes due 2012 are convertible into common stock at $23.69 per share; investors have an option to purchase another $50M of the notes (2/9) |
Scolr Pharma |
Private placement of stock |
3.75S |
$15 |
The shares were sold at $4 each; the placement agent, Taglich Brothers, received a fee and five- year warrants to purchase up to 75,000 shares (2/8) |
Tm Bioscience |
Bought-deal financing |
4.33S |
C$9.3 (US$7.6) |
The shares were sold at C$2.15 through a syndicate of underwriters led by Orion Securities Inc. and including Dlouhy Merchant Group (2/3) |
Vernalis plc |
Private placement and open offer |
43.3S |
£30.3 (US$57.9) |
The shares were sold at 70 pence each; existing shareholders were offered five new shares for every 18 ordinary shares held (2/24) |
XOMA Ltd. |
Private placement of convertible notes |
N/A |
$60 |
The 6.5% senior notes are convertible into common stock at an initial price of $1.87; purchasers have an option to buy up to $5M more of the notes (2/1) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
